Latest news
Latest news
Building climate-resilient health clinics
When Mother Nature strikes—think triple-digit heatwaves, wildfires, hurricanes—vulnerable populations are at risk of missing out on much-needed healthcare. For Earth Day, learn how Johnson & Johnson is helping community clinics protect patients.
What to know about low vision
Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
More from Johnson & Johnson
Latest news
What you need to know about Johnson & Johnson’s 2024 first-quarter earnings
Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
Latest news
Johnson & Johnson named to Fortune’s 2024 America’s Most Innovative Companies list
The company’s drive to develop novel solutions for the world’s toughest healthcare challenges has earned it a spot on Fortune’s second annual list.
September 20, 2023
Meet 3 leaders who are breaking new ground for women in healthcare
For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
Innovation
What is an orphan drug?
The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
Caring & giving
3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection
In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
What is cardiac ablation?
For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
Press releases
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse1 Approval is based on results from the PHASE 3 CARTITUDE-4 study, in which treatment with cilta-cel in 1-3 prior lines of therapy reduced the risk of disease progression or death by 74 percent compared to standard therapies1
Johnson & Johnson Reports Q1 2024 Results
2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* · Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the midpoint for Full-Year 2024 operational sales5 and adjusted operational EPS guidance
Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting
Analysis of clinical and non-clinical studies supports the investigational treatment’s potential for rapid, deep and sustained immunoglobulin G (IgG) lowering
